List of Excipients in Branded Drug CARBIDOPA-LEVODOPA

Generic Drugs Containing CARBIDOPA-LEVODOPA

Company	Ingredient	NDC	Excipient
TruPharma LLC	carbidopa and levodopa	52817-390	CELLULOSE, MICROCRYSTALLINE
TruPharma LLC	carbidopa and levodopa	52817-390	CROSPOVIDONE
TruPharma LLC	carbidopa and levodopa	52817-390	FD&C BLUE NO. 2--ALUMINUM LAKE
TruPharma LLC	carbidopa and levodopa	52817-390	HYDROXYPROPYL CELLULOSE
TruPharma LLC	carbidopa and levodopa	52817-390	MAGNESIUM STEARATE
Coupler LLC	carbidopa and levodopa	67046-1507	CELLULOSE, MICROCRYSTALLINE
Coupler LLC	carbidopa and levodopa	67046-1507	CROSPOVIDONE

What are the Most Frequently-Used Excipients in CARBIDOPA-LEVODOPA?

# Of NDCs	Excipient
5	CELLULOSE, MICROCRYSTALLINE
5	CROSPOVIDONE
2	D&C YELLOW NO. 10 ALUMINUM LAKE
1	FD&C BLUE NO. 2 ALUMINUM LAKE
2	FD&C BLUE NO. 2--ALUMINUM LAKE
5	HYDROXYPROPYL CELLULOSE
5	MAGNESIUM STEARATE

Carbidopa-Levodopa Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Carbidopa-levodopa remains a large, technically difficult reformulation market. The strongest commercial opportunities are not simple generic tablets. They are dosage forms that improve gastric delivery, reduce dosing frequency, smooth plasma exposure, protect levodopa from oxidation, or provide rapid rescue therapy. Existing products show that multiparticulate modified-release systems, intestinal infusion, inhalation and dual-release granules can support differentiated pricing and patent protection.

What is the commercial opportunity for carbidopa-levodopa excipient innovation?

The opportunity is driven by the limitations of conventional immediate-release tablets:

• Variable gastric emptying produces inconsistent onset.
• Levodopa has a short plasma half-life, generally about 1 to 2 hours.
• Large neutral amino acids compete with levodopa for intestinal transport.
• Patients often require multiple daily doses.
• Dyskinesia and "off" periods increase as Parkinson's disease progresses.
• Oral absorption becomes less reliable in patients with advanced disease or gastroparesis.[1]

Excipient innovation can address these problems without changing the active ingredients. The most commercially attractive targets are:

Opportunity	Excipient or platform strategy	Commercial objective
Longer duration	Ethylcellulose, hypromellose, polymer-coated pellets, multiparticulates	Reduce dosing frequency
Faster onset	Rapid-disintegration matrix, highly wettable granules, superdisintegrants	Shorten time to clinical effect
More predictable exposure	Gastroretentive polymers, floating systems, mucoadhesive excipients	Limit variability from gastric emptying
Protection from degradation	Antioxidants, chelators, oxygen-control packaging, pH modifiers	Improve stability and shelf life
Rescue treatment	Inhalation-grade carriers and particle engineering	Treat sudden "off" episodes
Advanced disease	Aqueous intestinal gel or continuous infusion vehicle	Bypass gastric and intestinal absorption variability
Pediatric or dysphagic use	Orally disintegrating tablets, granules, taste masking	Expand administration options
Differentiated dual release	Separate immediate-release and extended-release populations	Combine rapid onset with sustained effect

The most defensible products combine several functions in a single delivery architecture. A basic tablet with a new lubricant or filler has limited pricing power and weak patent scope.

Which carbidopa-levodopa products demonstrate excipient-based differentiation?

Sinemet and generic immediate-release tablets

Sinemet, marketed by Merck and later associated with branded and authorized generic supply, established the conventional carbidopa-levodopa tablet. Generic versions are widely available in strengths including 10/100 mg, 25/100 mg and 25/250 mg.

The core excipient strategy is conventional oral solid dosage technology: a compressed matrix using fillers, binders, disintegrants, lubricants and coating materials. The commercial value is primarily low cost and broad availability rather than formulation exclusivity.

For a new entrant, substituting one conventional excipient for another is unlikely to create a durable moat. The strongest generic opportunity is manufacturing efficiency, reliable supply, dose flexibility and regulatory equivalence.

Rytary extended-release capsules

Rytary, developed by Impax Laboratories and now commercialized by Amneal Pharmaceuticals, uses extended-release capsules containing multiparticulate beads. The product combines immediate-release and extended-release fractions to provide early levodopa exposure followed by a longer release profile.[2]

Its excipient and manufacturing platform includes polymer-coated particles and capsule filling. Typical multiparticulate components include sugar or drug-containing cores, polymer binders, film-forming materials, controlled-release polymers, anti-tacking agents and plasticizers.

The strategic value of the platform is greater than the value of any individual excipient. Protection can be directed to:

• Drug-loaded bead composition.
• Coating thickness and polymer ratios.
• Immediate-release versus extended-release bead populations.
• Capsule dose architecture.
• Dissolution profile across gastric and intestinal pH.
• Manufacturing methods for uniform bead coating.

Rytary demonstrates that a complex oral dosage form can support branded pricing despite the availability of immediate-release generic tablets. It also creates a substitution barrier because an ANDA applicant must match the release profile and demonstrate bioequivalence across multiple strengths.

Duopa intestinal gel

Duopa, developed by AbbVie, delivers carbidopa-levodopa as a continuous intestinal gel through a portable pump and percutaneous endoscopic gastrojejunostomy tube. The formulation bypasses much of the variability associated with gastric emptying and oral dosing.[3]

Its commercial differentiation is based on the full system:

• Aqueous carbidopa-levodopa gel.
• Cassette and pump.
• Enteral tube.
• Continuous administration protocol.
• Device and formulation manufacturing controls.

Excipient opportunities in intestinal gel include suspension stability, pH control, oxidation protection, viscosity control, microbiological preservation and compatibility with the cassette and tubing. The formulation must remain pumpable while maintaining drug concentration during storage and use.

This product is not a conventional excipient-only opportunity. The strongest protection is likely to come from the combined formulation, container, pump and method-of-treatment architecture.

Inbrija inhalation powder

Inbrija, marketed by Acorda Therapeutics, is an inhaled levodopa product for intermittent treatment of "off" episodes. It does not contain carbidopa. Its delivery system uses engineered dry-powder particles and a dedicated inhaler.[4]

Excipient and particle-engineering opportunities include:

• Lactose or other carrier particles.
• Micronized levodopa.
• Surface modification to improve aerosolization.
• Moisture control.
• Particle-size distribution.
• Device resistance and emitted dose.
• Capsule and inhaler compatibility.

The product demonstrates that levodopa can support a non-oral rescue market. The commercial constraint is the need for a dedicated device and patient training. A competing inhaled formulation could target lower device cost, improved lung deposition, fewer capsules per dose or better usability.

Crexont extended-release capsules

Crexont, developed by Amneal, received FDA approval in 2024 for Parkinson's disease and parkinsonism. It uses immediate-release and extended-release carbidopa-levodopa granules in a capsule.[5]

The formulation strategy is significant because it separates rapid-release and sustained-release functions within a single dosage form. This architecture can be protected through:

• Granule composition.
• Distinct immediate-release and extended-release populations.
• Polymer selection and coating.
• Granule size distribution.
• Drug loading.
• Dissolution targets.
• Capsule dose combinations.

Crexont competes directly with Rytary and indirectly with generic Sinemet. Its commercial pitch is fewer daily doses and more consistent motor control, but payer acceptance will depend on whether reduced dosing burden translates into lower total treatment cost.

What excipients are most relevant to carbidopa-levodopa formulation development?

Modified-release polymers

Ethylcellulose is widely used for water-insoluble release-controlling films. Hypromellose can create hydrophilic matrices or coating layers. Polyvinyl acetate-based systems, methacrylate copolymers and other film-forming polymers can adjust pH-dependent or time-dependent release.

Multiparticulate systems are usually preferable to a single monolithic matrix where dose proportionality, gastric transit and reduced dose dumping are priorities. They also allow separate immediate-release and extended-release fractions.

Disintegrants and wetting agents

Crospovidone, croscarmellose sodium and sodium starch glycolate can improve tablet disintegration. Polysorbates, sodium lauryl sulfate and other wetting agents can improve powder wetting and release consistency, but their concentration must be controlled because surfactants can alter coating integrity and gastrointestinal tolerability.

Antioxidants and chelators

Levodopa is susceptible to oxidation. Excipient strategies can include sodium metabisulfite or related antioxidants where permitted and clinically acceptable, chelating agents such as edetate compounds, oxygen-limiting packaging and pH optimization. These approaches require careful assessment because oxidation-control excipients can affect safety, color, dissolution and regulatory acceptability.

Packaging is often as important as the formulation. High-barrier blister films, desiccants, nitrogen flushing and low-oxygen filling can produce a stronger stability package than an excipient change alone.

Gastroretentive and mucoadhesive systems

Floating tablets, swellable polymers and mucoadhesive polymers could prolong gastric residence. The technical rationale is strong because levodopa absorption occurs mainly in the upper small intestine, and delayed gastric emptying can reduce or delay delivery to the absorption site.[1]

The commercial risk is clinical variability. A gastroretentive system must retain the drug without causing erratic release, obstruction risk or food-dependent exposure. A successful product would need strong clinical evidence rather than dissolution data alone.

Taste-masking and orally disintegrating systems

Orally disintegrating tablets, mini-tablets, oral granules and sprinkle capsules can address dysphagia, a frequent issue in advanced Parkinson's disease. Taste masking may use polymer coatings, ion-exchange resins, lipid barriers or sweetener systems.

These products can target nursing homes, home care and patients unable to swallow conventional tablets. Their patent value is generally moderate unless the formulation also provides rapid onset, dose flexibility or controlled release.

What formulations are protected by patents and regulatory exclusivity?

Patent protection in this market generally attaches to the formulation architecture rather than to the active ingredients. Carbidopa and levodopa are old compounds, and basic immediate-release compositions have limited remaining exclusivity value.

Product or platform	Main differentiation	Likely protection focus	Regulatory pathway
Generic Sinemet equivalent	Immediate-release tablet	Limited formulation claims, process know-how	ANDA
Rytary	Multiparticulate dual release	Beads, coatings, release profile, dose architecture	NDA
Duopa	Continuous intestinal gel and pump	Gel composition, cassette, pump, treatment method	NDA
Inbrija	Inhaled levodopa powder	Particle engineering, carrier, device, emitted dose	NDA
Crexont	Immediate-release and extended-release granules	Granule populations, coatings, dissolution, manufacturing	NDA

FDA approval does not make every formulation patentable. A patent must generally show novelty, nonobviousness and adequate written description. The most valuable claims cover a reproducible relationship between excipient composition, release behavior and clinical performance.

What is the Orange Book status of carbidopa-levodopa products?

The FDA Orange Book lists approved drug products and relevant patents submitted by NDA holders. Orange Book-listed patents can create an ANDA certification and litigation pathway for generic applicants.[6]

For carbidopa-levodopa:

• Immediate-release generic tablets are established ANDA products.
• Rytary, Duopa and Inbrija are NDA-based products with formulation, device or method-of-use protection that may affect generic entry.
• Crexont is a newer NDA product with a developing patent and exclusivity profile.
• Orange Book status must be evaluated product by product because patent listings, expiration dates and certifications can change through supplements, litigation and regulatory updates.

A commercial diligence review should separate:

1. Active ingredient patents.
2. Formulation patents.
3. Device patents.
4. Method-of-use patents.
5. Pediatric exclusivity.
6. Regulatory exclusivity.
7. Unlisted manufacturing and trade-secret barriers.

When does carbidopa-levodopa lose exclusivity?

The active ingredients have long lost basic compound exclusivity. The relevant exclusivity dates are formulation-specific.

The principal commercial sequence is:

Period	Market event	Competitive effect
Historical	Basic carbidopa-levodopa products mature	Broad generic availability
2010s	Rytary, Duopa and Inbrija introduce differentiated delivery	Specialty pricing and device barriers
2024 onward	Crexont enters the extended-release segment	New branded competition
Future	Product-specific patents expire or are invalidated	Potential ANDA entry
Post-expiration	Formulation and device alternatives expand	Price erosion depends on substitution and payer coverage

There is no single "carbidopa-levodopa patent expiration date." The relevant date depends on the branded product, listed patent, pediatric extension, patent-term adjustment and any settlement agreement.

Which companies compete in the carbidopa-levodopa market?

The principal commercial groups include:

• Amneal Pharmaceuticals: Rytary and Crexont.
• AbbVie: Duopa.
• Acorda Therapeutics: Inbrija.
• Generic manufacturers: Teva, Viatris, Sun Pharma, Endo and other ANDA holders, depending on product and market.
• Specialty and development-stage companies: firms pursuing continuous subcutaneous, intestinal, inhaled, transdermal or novel oral delivery.

The most direct branded competition is between Rytary and Crexont. Duopa competes for advanced patients with severe motor fluctuations, while Inbrija competes in the episodic rescue segment.

How does Rytary compare with Crexont?

Attribute	Rytary	Crexont
Developer	Impax, now Amneal	Amneal
Dosage form	Multiparticulate extended-release capsule	Immediate-release and extended-release granules
Clinical objective	Longer levodopa exposure and fewer doses	Rapid onset plus sustained exposure
Competitive reference	Generic immediate-release tablets and Duopa	Rytary and generic immediate-release tablets
Key technical barrier	Bead coating and release architecture	Granule populations and dual-release performance
Commercial risk	Dose conversion complexity and cost	Payer differentiation and clinical adoption
Patent value	Multiparticulate formulation and release claims	Granule composition, release profile and manufacturing claims

Crexont may compete effectively if it demonstrates simpler conversion, reliable onset and lower daily dosing burden. Rytary has first-mover experience and an established physician base. Both products remain exposed to generic substitution pressure from low-cost immediate-release tablets.

What generic entry risks exist for branded carbidopa-levodopa products?

Paragraph IV challenges

An ANDA applicant can submit a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. The NDA holder may then file patent litigation, triggering a statutory stay of FDA approval for up to 30 months under applicable conditions.[7]

For complex products, the highest-risk challenges usually target:

• Narrow formulation claims.
• Obviousness of polymer combinations.
• Lack of written description for broad release profiles.
• Non-infringement based on different coatings or granules.
• Failure of the listed patent to claim the approved product accurately.

Biosimilar risk

Biosimilar risk is not material for conventional carbidopa-levodopa tablets, capsules, inhaled powder or intestinal gel because these are small-molecule drug products rather than biologics. The relevant threat is generic or hybrid approval, not biosimilar substitution.

Generic launch scenarios

A generic entrant may pursue:

• Direct substitution for immediate-release tablets.
• A 505(j) ANDA for an extended-release capsule.
• A 505(b)(2) application for a modified-release, inhaled or liquid product.
• A device combination product requiring additional comparative performance evidence.

Complex release systems create higher development costs and greater risk of FDA deficiencies. That risk can delay launch even when the core active ingredients are inexpensive.

How strong is the patent estate for carbidopa-levodopa reformulations?

The estate is strongest when it combines composition, performance and manufacturing claims.

Stronger claim categories

• Defined multiparticulate bead or granule populations.
• Specific coating polymers and weight ratios.
• Release profiles tied to pharmacokinetic performance.
• Dual-release dosage forms with measurable clinical advantages.
• Drug-device combinations.
• Sterile or low-bioburden intestinal gel systems.
• Manufacturing processes that produce a difficult-to-replicate microstructure.

Weaker claim categories

• Broad use of common fillers or lubricants.
• Generic claims to "controlled release" without a distinctive structure.
• Conventional antioxidants used at routine concentrations.
• Simple dose combinations lacking unexpected performance.
• Method-of-use claims that merely restate known Parkinson's disease treatment.

Trade secrets can materially supplement patents. Critical know-how may include coating conditions, granulation endpoints, oxygen-control procedures, bead-size sorting, capsule filling and device compatibility.

What licensing and partnership opportunities exist?

Commercially attractive licensing targets include:

• Polymer-coated multiparticulate platforms.
• Gastroretentive and mucoadhesive oral systems.
• Inhalation particle-engineering technology.
• Continuous infusion pumps and cassette systems.
• Stability-enhancing excipient and packaging platforms.
• Taste-masking technology for dysphagia products.
• Manufacturing technologies for uniform drug-layered beads or granules.

A licensing transaction is more valuable when the technology has prior human data, scalable manufacturing and a defined regulatory pathway. Excipient suppliers with regulatory precedent in oral, inhaled or enteral products can reduce development risk, but the value depends on whether the excipient is already qualified for the intended route.

What FDA and CMC issues affect excipient commercialization?

FDA review will focus on more than the identity of the excipients. Key issues include:

• Excipient safety at chronic doses.
• Route-specific qualification for inhaled or intestinal products.
• Nitrosamine, elemental impurity and residual-solvent controls.
• Extractables and leachables from tubing, capsules and devices.
• Dissolution robustness across pH and agitation conditions.
• Uniformity of multiparticulate coating.
• Stability of levodopa against oxidation.
• Compatibility with food, enteral nutrition and co-administered drugs.
• Bioequivalence for modified-release products.
• Device performance and delivered dose for inhaled products.

For a reformulation, the clinical claim must match the excipient strategy. A smoother dissolution curve alone may not justify premium pricing unless it improves "off" time, reduces dosing frequency, improves adherence or lowers rescue-medication use.

Key Takeaways

• The basic carbidopa-levodopa tablet market is mature and price competitive.
• The best excipient opportunities involve modified release, gastric delivery, oxidation control, inhalation or continuous infusion.
• Multiparticulate dual-release systems have the strongest demonstrated commercial precedent.
• Rytary and Crexont are the main branded oral extended-release benchmarks.
• Duopa shows the value of combining formulation, device and administration method.
• Inbrija creates a separate inhaled rescue market, although it contains levodopa without carbidopa.
• Generic challenges will focus on formulation, release-profile and device patents rather than active-ingredient patents.
• Biosimilar competition is not relevant because carbidopa-levodopa products are small-molecule drugs.
• Patent strength depends on defined product architecture, clinical performance and reproducible manufacturing.
• The highest-value licensing targets are technologies with human data, scalable CMC and a clear FDA pathway.

FAQs About Carbidopa-Levodopa Excipient Strategy

Can a new excipient create a patentable carbidopa-levodopa product?

Yes, but the excipient alone is rarely sufficient. Patent strength is higher when the excipient produces a defined release profile, stability advantage, pharmacokinetic improvement or clinical benefit.

Is gastroretentive carbidopa-levodopa commercially attractive?

Yes. Gastric retention directly addresses delayed gastric emptying and inconsistent levodopa absorption. Clinical variability and food effects remain the main development risks.

Can carbidopa-levodopa be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could target dysphagia and caregiver administration. Taste masking, dose loading and stability are the principal formulation constraints.

Does inhaled carbidopa-levodopa compete directly with Inbrija?

An inhaled product containing both carbidopa and levodopa would compete with Inbrija in the rescue market but would face more complex formulation and inhalation-performance requirements.

Which excipient platform offers the best commercial return?

Multiparticulate immediate-release and extended-release granules offer the strongest balance of technical feasibility, clinical differentiation, manufacturing scalability and patentability.

References

1. National Institute for Health and Care Excellence. (2017). Parkinson's disease in adults: Diagnosis and management. NICE guideline NG71.

2. U.S. Food and Drug Administration. (2015). Rytary prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Duopa prescribing information. FDA.

4. U.S. Food and Drug Administration. (2018). Inbrija prescribing information. FDA.

5. U.S. Food and Drug Administration. (2024). Crexont prescribing information. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).